Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2003

View Archived Issues

New GSK-3 inhibitors in early development at Novo Nordisk

Vertex claims novel inhibitors of GSK-3, Aurora-2 and CDK2

Novel alpha4 integrin antagonists discovered at Ajinomoto

Merck KGaA patents new insulin secretagogues

Novel CRF1-selective ligands designed by Salk Institute scientists

Modulators of peroxisome proliferator-activated receptors in Novo Nordisk pipeline

AstraZeneca describes new NOS inhibitors for arthritis and pain

New antiangiogenic peptides with utility in cancer claimed by Abbott

Somatostatin analogues and their use in cancer diagnosis and treatment reported by Mallinckrodt

Pharmagenesis and Pierre Fabre sign license agreement for PG-490-88Na

MicroIslet and Scripps enter islet cell transplantation collaboration

FDA advisory committee recommends additional analyses of Vitrase data

Protein Design Labs licenses SMART M195 antibody to Actinium

Anidulafungin as effective as fluconazole in esophageal candidiasis in phase III trial

Human Genome Sciences develops ABthrax

Helicide approved in Canada for H. pylori eradication

Preparations for late-stage phase II trial of Product R for AIDS

Tanabe Seiyaku to commercialize Actiq in Japan

Levitra introduced in Germany for ED

Immunological and virological effects induced by enfuvirtide in HIV-infected patients

Mirtazapine safe and effective in posttraumatic stress disorder

HOPE data on the costs of ramipril therapy in cardiovascular diseases

DTI-015 affords 40% cure rate and over 400% increase in life span in rats with brain cancer

Acetylcysteine associated with lower incidence of cardiovascular events in end-stage renal failure

Calcimimetic reduces PTH levels in hyperparathyroidism secondary to hemodialysis

Novartis to acquire Pfizer incontinence drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...